News

The company has also secured an additional $2 million optional financing commitment in this series. Panacea Pharmaceuticals chairman & CEO/CSO Hossein Ghanbari said: "Our lead drug candidate, our

LAL-D is caused by genetic mutations that lead to a marked decrease or loss in LAL enzyme activity in the lysosomes across several body tissue. Kanuma reduces substrate

Novartis unit Sandoz is seeking approval for all indications included in the label of the reference product. More than 120 million people in the European Union are living

The new therapies will be developed using BioAtla’s conditionally active biologics (CAB) platform and Pfizer’s antibody drug conjugate (ADC) payloads. The deal gives both companies a license to

G204 is a double-blind, placebo-controlled cumulative dose selection study for grass allergic rhinitis, which follows the successful completion of the GMM102 (G102) safety study, which demonstrated safety of

The OPTIC-2L (Optimizing Ponatinib Treatment In CML, Second Line) trial is designed to investigate the efficacy and safety of ponatinib, administered at two starting doses, compared with nilotinib,

KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein

Both products are formulated with aloe vera and Cortivera™ contains 0.5% hydrocortisone and Cortivera Plus™ contains 1% hydrocortisone. Both are available in cream and ointment form in order

The financing, which was supported by institutional investors in the US and Europe, will support the continued clinical development of the company’s ERY-ASP/GRASPA. ERY-ASP/GRASPA is designed specifically to